FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W68627> ?p ?o ?g. }

• W68627 endingPage "314" @default.
• W68627 startingPage "305" @default.
• W68627 abstract "Liver biopsy to assess fibrosis is invasive and prone to sampling error. While algorithms of serum markers to predict fibrosis stage have been described for chronic hepatitis C, these cannot be applied equally well to hepatitis B.We therefore determined 9 serum fibrosis markers, liver biochemical tests and ultrasound parameters in 109 consecutive adult patients with chronic hepatitis B and D. All patients had compensated liver disease. Using the METAVIR score, advanced disease was defined as fibrosis stage ≥F2, and active inflammation as grade ≥A2. A gold standard was created considering splenomegaly and/or platelets <150,000 as indicators of advanced fibrosis irrespective of histology. Area under receiver operating characteristics curves was used for assessment of single markers and odds ratio for their combinations.Patients with advanced disease were older, had lower albumin, higher gamma glutamyl transferase and lower platelet. Levels of 6 of the 9 fibrosis markers, tissue inhibitor of metalloproteinases-1, procollagen type III aminoterminal propeptide, matrix metalloproteinase-2, laminin, hyaluronan and collagen IV correlated with advanced fibrosis. Markers useful for fibrosis prediction also predicted marked inflammation. Using the gold standard, age, prothrombin time, gamma glutamyl transferase and albumin were independent predictors of fibrosis with odds ratio's of 3.11, 4.18, 3.35 and 5.25, respectively. Their combined use predicted fibrosis with an odds ratio of 228.8. Tissue inhibitor of metalloproteinases-1 and hyaluronan were powerful predictors of fibrosis (Odds ratio's of 8.65 and 8.38). Their combined use revealed an odds ratio of 28.6, when compared with the gold standard.In conclusion, advanced liver fibrosis in chronic hepatitis B and D may be predicted with use of these two fibrosis markers." @default.
• W68627 created "2016-06-24" @default.
• W68627 creator A5009708909 @default.
• W68627 creator A5013841764 @default.
• W68627 creator A5017559121 @default.
• W68627 creator A5022092357 @default.
• W68627 creator A5024219904 @default.
• W68627 creator A5041665033 @default.
• W68627 creator A5062823090 @default.
• W68627 creator A5066406395 @default.
• W68627 creator A5066415040 @default.
• W68627 creator A5070174845 @default.
• W68627 creator A5075098947 @default.
• W68627 creator A5083794629 @default.
• W68627 creator A5085243200 @default.
• W68627 creator A5088602858 @default.
• W68627 date "2011-06-01" @default.
• W68627 modified "2023-10-06" @default.
• W68627 title "Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D" @default.
• W68627 cites W1577206569 @default.
• W68627 cites W1706834400 @default.
• W68627 cites W172224148 @default.
• W68627 cites W1814037092 @default.
• W68627 cites W1943302144 @default.
• W68627 cites W1943386879 @default.
• W68627 cites W1964701798 @default.
• W68627 cites W1967711533 @default.
• W68627 cites W1970368657 @default.
• W68627 cites W1974511288 @default.
• W68627 cites W1988954500 @default.
• W68627 cites W1989572172 @default.
• W68627 cites W1997064567 @default.
• W68627 cites W1997865776 @default.
• W68627 cites W1998626573 @default.
• W68627 cites W2000538721 @default.
• W68627 cites W2001239798 @default.
• W68627 cites W2002163127 @default.
• W68627 cites W2002749846 @default.
• W68627 cites W2009575651 @default.
• W68627 cites W2011934019 @default.
• W68627 cites W2013085780 @default.
• W68627 cites W2013716066 @default.
• W68627 cites W2014787018 @default.
• W68627 cites W2023685519 @default.
• W68627 cites W2031732449 @default.
• W68627 cites W2035793488 @default.
• W68627 cites W2042062317 @default.
• W68627 cites W2044803173 @default.
• W68627 cites W2045478709 @default.
• W68627 cites W2046252545 @default.
• W68627 cites W2056259629 @default.
• W68627 cites W2060385743 @default.
• W68627 cites W2069029705 @default.
• W68627 cites W2079246556 @default.
• W68627 cites W2079916847 @default.
• W68627 cites W2080437966 @default.
• W68627 cites W2086962806 @default.
• W68627 cites W2092607950 @default.
• W68627 cites W2095337268 @default.
• W68627 cites W2109037928 @default.
• W68627 cites W2114376411 @default.
• W68627 cites W2132290252 @default.
• W68627 cites W2134819112 @default.
• W68627 cites W2136336812 @default.
• W68627 cites W2139966914 @default.
• W68627 cites W2144935009 @default.
• W68627 cites W2149346967 @default.
• W68627 cites W2149418352 @default.
• W68627 cites W2151769300 @default.
• W68627 cites W2156015715 @default.
• W68627 cites W2166826446 @default.
• W68627 cites W2404681156 @default.
• W68627 cites W28646162 @default.
• W68627 cites W34619435 @default.
• W68627 cites W2707659916 @default.
• W68627 cites W3145006287 @default.
• W68627 doi "https://doi.org/10.4318/tjg.2011.0217" @default.
• W68627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21805422" @default.
• W68627 hasPublicationYear "2011" @default.
• W68627 type Work @default.
• W68627 sameAs 68627 @default.
• W68627 citedByCount "20" @default.
• W68627 countsByYear W686272012 @default.
• W68627 countsByYear W686272013 @default.
• W68627 countsByYear W686272015 @default.
• W68627 countsByYear W686272016 @default.
• W68627 countsByYear W686272017 @default.
• W68627 countsByYear W686272018 @default.
• W68627 countsByYear W686272020 @default.
• W68627 countsByYear W686272021 @default.
• W68627 countsByYear W686272022 @default.
• W68627 countsByYear W686272023 @default.
• W68627 crossrefType "journal-article" @default.
• W68627 hasAuthorship W68627A5009708909 @default.
• W68627 hasAuthorship W68627A5013841764 @default.
• W68627 hasAuthorship W68627A5017559121 @default.
• W68627 hasAuthorship W68627A5022092357 @default.
• W68627 hasAuthorship W68627A5024219904 @default.

• next